The use of low-molecular-weight heparins in pregnancy - How safe are they?

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 6, 2007, Pages 573-577

  Deruelle, Philippe ^a   Coulon, Capucine ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

Complications; Fetus; Neonate; Pregnancy; Safety

Indexed keywords

CALCIUM; DANAPAROID; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN D;

ALLERGIC REACTION; BLEEDING; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSS REACTION; DELIVERY; DRUG SAFETY; FETUS WASTAGE; HIGH RISK PREGNANCY; HUMAN; LIVE BIRTH; NEONATAL HEMORRHAGE; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN ALLERGY; SKIN BRUISING; SKIN CYST; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION;

EID: 36248931399     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f10e33     Document Type: Review

References (50)

1. Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005; 128:593-601.
2. Folkeringa N, Brouwer JL, Korteweg FJ, et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007; 136:656-661. Beyond the safety, LMWH increase the live birth rate in women with thrombophilia.
3. Dimitrakakis C, Papageorgiou P, Papageorgiou I, et al. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 2000; 30:243-248.
4. Omri A, Delaloye JF, Andersen H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989; 61:55-56.
5. Robin F, Lecuru F, Desfeux P, et al. Anticoagulant therapy in pregnancy. Eur J Obstet Gynecol Reprod Biol 1999; 83:171-177.
6. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401-407.
7. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108:1134-1140.
8. Lindqvist PG, Dahlback B. Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy. Thromb Haemost 2000; 84:140-141.
9. Blanco-Molina A, Trujillo-Santos J, Criado J, et al. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost 2007; 97:186-190. The RIETE registry followed up 11 630 patients with acute venous thromboembolism, including 848 women under 47 years and 136 pregnant women. The safety of LMWH was similar in pregnant and nonpregnant patients.
10. Kominiarek MA, Angelopoulos SM, Shapiro NL, et al. Low-molecular-weight heparin in pregnancy: peripartum bleeding complications. J Perinatol 2007; 27:329-334. This study examined the risk of peripartum bleeding associated with LMWH. When LMWH treatment is discontinued at least 24 h before delivery, the risk of postpartum bleeding is not increased: 11% in treated and 8.2% in untreated patients.
11. Maslovitz S, Many A, Landsberg JA, et al. The safety of low molecular weight heparin therapy during labor. J Matern Fetal Neonatal Med 2005; 17:39-43.
12. Lee RH, Goodwin TM. Massive subchorionic hematoma associated with enoxaparin. Obstet Gynecol 2006; 108 (3 Pt 2):787-789. This paper reports a major hematoma related to LMWH treatment and reminds us that LMWH may potentiate unpredictable bleeding events in pregnancy.
13. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
14. Fausett MB, Vogtlander M, Lee RM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001; 185:148-152.
15. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005; 93:63-69.
16. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost 2007; 97:496-497. This paper describes two cases of successful management with fondaparinux of pregnant women with heparin intolerance. There is some concern about the transplacental passage of this new anticoagulant.
17. Mazzolai L, Hohlfeld P, Spertini F, et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108:1569-1570. This paper describes two cases of successful management with fondaparinux of pregnant women with heparin intolerance. There is some concern about the transplacental passage of this new anticoagulant.
18. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350:1914-1915.
19. Brenner B, Bar J, Ellis M, et al. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the LIVE-ENOX study. Fertil Steril 2005; 84:770-773.
20. Deruelle P, Denervaud M, Hachulla E, et al. Use of low-molecular-weight heparin from the first trimester of pregnancy: a retrospective study of 111 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 2006; 127:73-78. This study focused on LMWH therapy started specifically during the first trimester. The use of LMWH for patients requiring anticoagulant treatment from the first trimester appears safe for both pregnant mother and fetus. No major adverse event was related to LMWH treatment.
21. Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vivo. Thromb Haemost 1998; 80:413-417.
22. Folwarczna J, Sliwinski L, Janiec W, Pikul M. Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vivo. Pharmacol Rep 2005; 57:635-645.
23. Murray WJ, Lindo VS, Kakkar VV, Melissari E. Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coagul Fibrinolysis 1995; 6:113-118.
24. Shaughnessy SG, Hirsh J, Bhandari M, et al. A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 1999; 93:1231-1236.
25. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77:39-43.
26. Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68:652-656.
27. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176:1062-1068.
28. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65:171-174.
29. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170:862-869.
30. Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 2000; 9:122-125.
31. Casele H, Haney EI, James A, et al. Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol 2006; 195:1109-1113. This prospective, randomized trial found the incidence of significant bone loss to be similar in LMWH therapy and unfractioned heparin therapy. Interestingly, most of patients received calcium±vitamin D supplementation. These data suggest that calcium supplementation may reduce the impact of heparin-induced osteoporosis. Daily calcium consumption is recommended for pregnant women receiving LMWH.
32. Brenner B, Hoffman R, Carp H, et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 3:227-229.
33. Uysal II, Karabulut AK, Ozdemir K, et al. Investigation of direct toxic and teratogenic effects of anticoagulants on rat embryonic development using in vitro culture method and genotoxicity assay. Anat Histol Embryol 2006; 35:84-92. This work demonstrated that LMWH have direct toxic and teratogenic effects on embryonic growth and development in cultured rat embryos. Fortunately, LMWH do not cross the placenta and have no direct effects on the embryo or fetus in vivo.
34. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668-672.
35. Blomback M, Bremme K, Hellgren M, et al. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy - a longitudinal safety study. Blood Coagul Fibrinolysis 1998; 9:1-9.
36. Dolitzky M, Inbal A, Segal Y, et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86:362-366. This randomized study compared the efficacy and safety of LMWH and aspirin in women with recurrent miscarriage. Live-birth rate was similar with both treatments. No maternal complications occurred in either group. Aspirin was associated with an increased number of neonatal complications: 4 versus 0% with LMWH.
37. Dulitzki M, Pauzner R, Langevitz P, et al. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87:380-383.
38. Wahlberg TB, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 European clinics. Haemostasis 1994; 24:55-56.
39. EUROCAT Report 8. Surveillance of congenital anomalies in Europe 1980-1999. Newtownabbey: University of Ulster; 2002.
40. Harenberg J, Schneider D, Heilmann L, Wolf H. Lack of antifactor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 1993; 23:314-320.
41. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901-908.
42. Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83:693-697.
43. Grandone E, Brancaccio V, Colaizzo D, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78:371-375.
44. Kupferminc MJ, Fait G, Many A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20:35-44.
45. Riyazi N, Leeda M, de Vries JI, et al. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998; 80:49-54.
46. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1:433-438.
47. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103:3695-3699.
48. Di Simone N, Caliandro D, Castellani R, et al. Low-molecular-weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999; 14:489-495.
49. Di Simone N, Di Nicuolo F, Sanguinetti M, et al. Low-molecular-weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta 2007; 28:298-304.
50. Erden O, Imir A, Guvenal T, et al. Investigation of the effects of heparin and low molecular weight heparin on E-cadherin and laminin expression in rat pregnancy by immunohistochemistry. Hum Reprod 2006; 21:3014-3018.